Globus Medical (GMED)
(Delayed Data from NYSE)
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
Zacks News
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical (GMED) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical (GMED) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GMED or PEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. PEN: Which Stock Is the Better Value Option?
Globus Medical, Inc. (GMED) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.
Globus Medical (GMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q1 Earnings
by Zacks Equity Research
Evaluate the expected performance of Globus Medical (GMED) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
GMED vs. PEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMED vs. PEN: Which Stock Is the Better Value Option?
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
by Zacks Equity Research
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
Here's Why Globus Medical (GMED) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical (GMED) Q4 Earnings Surpass, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.